Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85 https://doi.org/10.5334/aogh.2419.

Satoh H, Okuma Y, Shinno Y, Masuda K, Matsumoto Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Ohe Y. Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapies. Lung Cancer. 2025;202:108453. https://doi.org/10.1016/j.lungcan.2025.108453.

Article  CAS  PubMed  Google Scholar 

Jung HA, Lee DH, Lim SM, Yu H, Yoon S, Kim D, Kim KP, Jeong H, Doh H, Lim S, Kim J, Zhao X, Horsburgh D, Patel D, Kim JA, Toh KC. Epidemiology and outcomes of non-small cell lung cancer in South Korea. JAMA Netw Open. 2024;7:e2355331. https://doi.org/10.1001/jamanetworkopen.2023.55331.

Article  PubMed  PubMed Central  Google Scholar 

Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, Ramalingam SS. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–7. https://doi.org/10.1200/JCO.2007.12.5435.

Article  PubMed  Google Scholar 

Lopez-Otin C, Pietrocola F, Roiz-Valle D, Galluzzi L, Kroemer G. Meta-hallmarks of aging and cancer. Cell Metab. 2023;35:12–35. https://doi.org/10.1016/j.cmet.2022.11.001.

Article  CAS  PubMed  Google Scholar 

Cordoba-Lanus E, Montuenga LM, Dominguez-de-Barros A, Oliva A, Mayato D, Remirez-Sanz A, Gonzalvo F, Celli B, Zulueta JJ, Casanova C. Oxidative damage and telomere length as markers of lung cancer development among chronic obstructive pulmonary disease (COPD) smokers. Antioxidants. 2024;13 https://doi.org/10.3390/antiox13020156.

Haston S, Gonzalez-Gualda E, Morsli S, Ge J, Reen V, Calderwood A, Moutsopoulos I, Panousopoulos L, Deletic P, Carreno G, Guiho R, Manshaei S, Gonzalez-Meljem JM, Lim HY, Simpson DJ, Birch J, Pallikonda HA, Chandra T, Macias D, et al. Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer. Cancer Cell. 2023;41:1242–1260e1246. https://doi.org/10.1016/j.ccell.2023.05.004.

Article  CAS  PubMed  Google Scholar 

Gao X, Yi L, Jiang C, Li S, Wang X, Yang B, Li W, Che N, Wang J, Zhang H, Zhang S. PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer. Front Immunol. 2023;14:1142428. https://doi.org/10.3389/fimmu.2023.1142428.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fekete M, Major D, Feher A, Fazekas-Pongor V, Lehoczki A. Geroscience and pathology: a new frontier in understanding age-related diseases. Pathol Oncol Res. 2024; https://doi.org/10.3389/pore.2024.1611623.

Lewis KN, Mele J, Hornsby PJ, Buffenstein R. Stress resistance in the naked mole-rat: the bare essentials - a mini-review. Gerontology. 2012; https://doi.org/10.1159/000335966.

Miller RA. Cell stress and aging: new emphasis on multiplex resistance mechanisms. J Gerontol A Biol Sci Med Sci. 2009;64:179–82. https://doi.org/10.1093/gerona/gln072.

Article  CAS  PubMed  Google Scholar 

Harper JM, Salmon AB, Chang Y, Bonkowski M, Bartke A, Miller RA. Stress resistance and aging: influence of genes and nutrition. Mech Ageing Dev. 2006;127:687–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lithgow GJ, Walker GA. Stress resistance as a determinate of C. elegans lifespan. Mech Ageing Dev. 2002;123:765–71.

Article  PubMed  Google Scholar 

Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136:823–37. https://doi.org/10.1016/j.cell.2009.02.024.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greenwood HE, Barber AR, Edwards RS, Tyrrell WE, George ME, Dos Santos SN, Baark F, Tanc M, Khalil E, Falzone A, Ward NP, DeBlasi JM, Torrente L, Soni PN, Pearce DR, Firth G, Smith LM, Vilhelmsson Timmermand O, Huebner A, et al. Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography. Nat Commun. 2024;15:10484. https://doi.org/10.1038/s41467-024-54852-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL. The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 2013;1:45–9. https://doi.org/10.1016/j.redox.2012.10.001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Wijst MG, Brown R, Rots MG. Nrf2, the master redox switch: the Achilles' heel of ovarian cancer? Biochim Biophys Acta. 2014;1846:494–509. https://doi.org/10.1016/j.bbcan.2014.09.004.

Article  CAS  PubMed  Google Scholar 

Leinonen HM, Kansanen E, Polonen P, Heinaniemi M, Levonen AL. Role of the Keap1-Nrf2 pathway in cancer. Adv Cancer Res. 2014;122:281–320. https://doi.org/10.1016/B978-0-12-420117-0.00008-6.

Article  CAS  PubMed  Google Scholar 

Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013;27:2179–91. https://doi.org/10.1101/gad.225680.113.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Menegon S, Columbano A, Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med. 2016;22:578–93. https://doi.org/10.1016/j.molmed.2016.05.002.

Article  CAS  PubMed  Google Scholar 

Leinonen HM, Kansanen E, Polonen P, Heinaniemi M, Levonen AL. Dysregulation of the Keap1-Nrf2 pathway in cancer. Biochem Soc Trans. 2015;43:645–9. https://doi.org/10.1042/BST20150048.

Article  CAS  PubMed  Google Scholar 

Furfaro AL, Traverso N, Domenicotti C, Piras S, Moretta L, Marinari UM, Pronzato MA, Nitti M. The Nrf2/HO-1 axis in cancer cell growth and chemoresistance. Oxid Med Cell Longev. 2016;2016:1958174. https://doi.org/10.1155/2016/1958174.

Article  CAS  PubMed  Google Scholar 

Milkovic L, Zarkovic N, Saso L. Controversy about pharmacological modulation of Nrf2 for cancer therapy. Redox Biol. 2017;12:727–32. https://doi.org/10.1016/j.redox.2017.04.013.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34:21–43. https://doi.org/10.1016/j.ccell.2018.03.022.

Article  CAS  PubMed  Google Scholar 

Adinolfi S, Patinen T, Jawahar Deen A, Pitkanen S, Harkonen J, Kansanen E, Kublbeck J, Levonen AL. The KEAP1-NRF2 pathway: targets for therapy and role in cancer. Redox Biol. 2023;63:102726. https://doi.org/10.1016/j.redox.2023.102726.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Glorieux C, Enriquez C, Gonzalez C, Aguirre-Martinez G, Buc CP. The multifaceted roles of NRF2 in cancer: friend or foe? Antioxidants. 2024;13 https://doi.org/10.3390/antiox13010070.

Ramisetti SV, Patra T, Munirathnam V, Sainath JV, Veeraiyan D, Namani A. NRF2 signaling pathway in chemo/radio/immuno-therapy resistance of lung cancer: looking beyond the tip of the iceberg. Arch Bronconeumol. 2024;60(Suppl 2):S59–66. https://doi.org/10.1016/j.arbres.2024.06.021.

Article  PubMed  Google Scholar 

Gyorffy B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br J Pharmacol. 2024;181:362–74. https://doi.org/10.1111/bph.16257.

Article  CAS  PubMed  Google Scholar 

Gyorffy B, Molnar B, Lage H, Szallasi Z, Eklund AC. Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS One. 2009;4:e5645. https://doi.org/10.1371/journal.pone.0005645.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gyorffy B. Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer. Geroscience. 2023;45:1889–98. https://doi.org/10.1007/s11357-023-00742-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gyorffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer.